MOLECULAR PARTNERS AG Stock Price, News & Analysis

Molecular Partners (NASDAQ: MOLN) will present additional preclinical proof-of-concept data on its logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation at SITC 2025 (Nov 5-9; poster Nov 7).

Preclinical results show the AND-gated Switch-DARPin selectively triggered T cell cytotoxicity only against cells co-expressing MSLN and EpCAM, improved T cell activation and proliferation with CD2/CD3 co-stimulation, and induced significant tumor regression in a xenograft model without systemic cytokine release, indicating a favorable safety signal.

Molecular Partners (NASDAQ: MOLN) will present updated Phase 1/2a data for MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), at the ASH Annual Meeting on December 7, 2025.

The poster summarizes first-in-human, multicenter, open-label results in relapsed/refractory AML and MDS/AML (ClinicalTrials.gov: NCT05673057). MP0533 showed an acceptable safety profile across dose ranges 1–9; densified dosing used in DR 8–9 appears tolerable and preliminary antitumor activity is described. The study is dosing in DR 10. Abstracts posted on the ASH website from 9:00 AM ET on November 3, 2025.

Molecular Partners (NASDAQ:MOLN / SIX:MOLN) filed an IND for MP0712 (212Pb DLL3 Radio-DARPin) with a Phase 1 start expected before year-end 2025 and first compassionate-care 203Pb images to be shown at the TRP Summit in November. Updated MP0533 Phase 1/2a data (AML) will be presented at ASH in December, with cohort 8 showing 3 of 8 evaluable responders and one patient >12 months on treatment.

Protocol approved for a Phase 2 investigator-initiated trial of MP0317 (FAP x CD40). Cash, equivalents and short-term deposits were CHF 105 million as of Sept 30, 2025, and the company expects runway until 2028. Full‑year 2025 operating expense guidance: CHF 55–60 million.

Molecular Partners (NASDAQ:MOLN) reported H1 2025 financial results and pipeline updates, highlighting progress in its clinical programs. The company's lead candidate MP0533 for AML/MDS showed promising results with >30% response rate in cohort 8, including durable responses. Their radio-DARPin program MP0712 is advancing toward Phase 1 trials, with IND filing expected by end of 2025.

The company appointed Martin Steegmaier, Ph.D. as CSO and announced a workforce reduction of up to 24%. With CHF 114 million in cash and deposits as of June 30, 2025, Molecular Partners has extended its runway into 2028. Expected operating expenses for 2025 are CHF 55-65 million.

Molecular Partners (NASDAQ:MOLN) has appointed Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the Executive Committee, effective October 1, 2025. Dr. Steegmaier brings extensive oncology drug development experience from his previous roles at SOTIO Biotech, MorphoSys, Roche, and Boehringer Ingelheim.

As CSO, Steegmaier will lead the research organization and advance the company's pipeline of targeted DARPin therapeutics for cancer patients, including Radio-DARPins and Switch-DARPins for logic-gated immune cell activation. His background includes significant experience in developing antibody-based therapeutics in immuno-oncology and hematology-oncology.

Molecular Partners (NASDAQ: MOLN) and Orano Med announced preclinical data for MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, at SNMMI 2025. The data showed MP0726 demonstrates high affinity and selective binding to membrane-bound MSLN, with favorable biodistribution in tumor models showing up to 34% tumor accumulation at 24 hours post-injection and a tumor-to-kidney ratio of 4.5. This represents the company's second Radio-DARPin program, with the first program MP0712 (targeting DLL3) expected to begin Phase 1 trials in H2 2025. The collaboration leverages Orano Med's expertise in targeted alpha-particle therapies with 212Pb and Molecular Partners' DARPin technology to address the challenge of shed MSLN acting as a decoy receptor in cancer treatment.

Molecular Partners (NASDAQ: MOLN) announced positive Phase 1/2a trial data for MP0533, their tetraspecific T-cell engager for relapsed/refractory acute myeloid leukemia (AML), at EHA 2025. In cohort 8, 3 out of 8 evaluable patients (>30%) achieved clinical responses after the first cycle, with one patient maintaining response beyond 6 months. The trial implemented an accelerated step-up dosing regimen, reaching target dose by day 12 instead of day 15, resulting in longer therapeutic exposure. Five out of 8 patients showed >50% blast reduction, with MP0533 demonstrating an acceptable safety profile. Based on these encouraging results, cohort 9 is now ongoing with further optimized dosing, and initial data is expected in H2 2025. Future study cohorts will evaluate MP0533 in combination with azacitidine/venetoclax.

Molecular Partners (NASDAQ: MOLN) has announced a strategic operational restructuring to enhance efficiency and extend its cash runway. The company plans to reduce its workforce by up to 40 positions (~24% of total) following a strategic review, primarily affecting research and associated functions. This restructuring will extend the company's cash reach into 2028, beyond the previous guidance of 2027. The company maintains its clinical timelines for MP0533 and MP0712, with data expected in H2 2025. CEO Patrick Amstutz emphasized that the decision aims to prioritize development of key clinical assets while ensuring future success. The company will provide affected employees with support including severance packages, job search assistance, coaching, and training opportunities. The restructuring implementation is expected to complete by end of 2025, with cost reductions becoming fully effective in early 2026.

Molecular Partners AG (NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, has announced its participation in two upcoming investor conferences. The management team will engage in fireside chats at: 1) The H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025 at 3:30pm ET, and 2) TD Cowen's 6th Annual Oncology Innovation Summit on May 28, 2025 at 10:00am ET. Both events will be accessible via webcast through the company's website in the investors section.